If MSB is looking for pharma giants, be prepared for it to drag out. There's not much a pharma giant can get from MSB because MSB doesn't make any real revenue streams. The more they open their books to industry giants, the more the shares will probably fall because the drug companies will see how lacklustre some of the experimental data really is. My guess is they will then add short positions.
It wouldn't surprise me if this has been going on for a while now.
A sale of MSB at anything near current prices would be an awesome deal for the company, especially the CEO.
I wouldn't value this business at more than $500 million.
For some reason the market still thinks its worth a whole lot more.
I still think we'll see much much lower prices.
DYOR
Add to My Watchlist
What is My Watchlist?
